SCT200
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer[1].
Product Specifications
UNSPSC
12352203
Target
EGFR
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
References & Citations
[1]Yang L, et al. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase II study. EBioMedicine. 2024 Feb;100:104966.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6217018-01 0.1 mL
FXN (frataxin, CyaY, FA, FARR, FRDA, MGC57199, X25) (MaxLight 550)
Ask
View Details MBS6217018-02 5x 0.1 mL
FXN (frataxin, CyaY, FA, FARR, FRDA, MGC57199, X25) (MaxLight 550)
Ask
View Details